Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 25, 2023

Clinical and Genomic Characteristics of Patients With HR+/HER2− Metastatic Breast Cancer After Progression on a CDK4/6 Inhibitor

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Clinical and Genomic Characteristics of Patients with HR+, HER2- Metastatic Breast Cancer Following Progression on a CDK4 and 6 Inhibitor
Clin. Cancer Res 2023 Jun 08;[EPub Ahead of Print], X Rao, Y Chen, J Beyrer, E Nash Smyth, C Morato Guimaraes, LM Litchfield, L Bowman, GW Lawrence, A Aggarwal, F Andre

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading